Regis Healthcare (ASX:REG) share price leaps on return to profit

The ASX healthcare share reported its FY21 results this morning.

| More on:
jump in asx share price represented by man leaping up from one wooden pillar to the next

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Regis Healthcare Ltd (ASX: REG) share price is leaping higher in morning trade, up 6.09% to $2.09 per share.

Below we take a look at the residential aged care provider’s financial results for the year ending 30 June (FY21).

Regis Healthcare share price up on FY21 results

Some top results likely moving the Regis Healthcare share price this morning:

  • Revenue from services increased 3.5% from FY20 to $701.4 million
  • Earnings before interest, taxes, depreciation and amortisation (EBITDA) of $137.8 million, down 2.7% year-on-year from $141.6 million
  • Net profit after tax (NPAT) of $19.9 million compared to a loss of $700,000 in FY20
  • Declared a final dividend of 4.63 cents, 50% franked

What happened during the reporting period for Regis Healthcare?

During the financial year, Regis reduced its debt by 39.8%, down to $142.4 million from $236.7 million at the end of FY20.

Average occupancy at its facilities edged 0.7% higher, to 88.9% from 88.2% the prior year.

As an operator of aged care facilities, COVID-19 mitigation measures were prioritised. All residents were offered vaccination via a government program. Regis also secured a separate provider, offering vaccines to all willing residents and employees.

As at 27 August, the company reports 78% of residents have had 2 doses while 58% of staff is double dosed. Regis received $7.7 million of government funding and $4.2 million of government grants in relation to costs incurred from COVID-19..

On 9 August, Regis announced that it had “identified potential underpayments of employee entitlements” going back 6 years and affecting some current and former employees. The review is ongoing, but Regis provided $35 million in the financial statements in relation to the issue. $7.1 million of this comes off the FY21 profit before income tax. The rest has been “recorded as a prior period restatement”.

Washington H. Soul Pattinson and Co. Ltd (ASX: SOL) moved to acquire Regis in September in an initial confidential, non-binding indicative proposal, valuing Regis Healthcare’s share price at $1.65. In November WHSP upped the offer to $1.85 per share.

Regis said the proposals were rejected as they “materially undervalued the company”. In January, WHSP withdrew its proposal.

The final dividend is payable 30 September. It takes the full-year dividends to 6.63 cents per share, or 100% of FY21 NPAT.

What did management say?

Commenting on the results, Regis’ CEO, Linda Mellors said:

Regis has performed strongly, responding to a range of significant events, including the threat to residents and employees from the global pandemic, an extended Royal Commission, the Australian government’s reform agenda, and various internal matters. Each challenge has been met with commitment and focus from a highly experienced team…

The company continues to review the progress of the COVID-19 pandemic and take necessary steps to protect the health, well-being and safety of residents, clients and employees.

What’s next for Regis Healthcare?

Looking ahead, management said it wasn’t prudent to provide guidance in the current macro-environment and the ongoing pandemic.

Mellors said:

Our focus on providing quality resident care, service and accommodation to support improved occupancy remains a high priority, while the reduction in debt places the company in a strong position to take advantage of various growth opportunities as they emerge.

The Regis Healthcare share price is up 68% over the past 12 months.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Washington H. Soul Pattinson and Company Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Earnings Results

A businessman jumps outdoors in sky between two rocks.
Earnings Results

Enero share price jumps 7% as earnings rocket

The markteing group has delivered its FY22 results. Here are the details.

Read more »

A group of business people pump the air and cheer.
Earnings Results

HiTech share price climbs 11% on record full-year results

Investors have reacted positively to the company's FY22 earnings.

Read more »

Two miners stand in front of a large black wall of coal.
Earnings Results

ASX All Ords share Stanmore Resources lifts 10% on ‘exciting’ half year

Stanmore posts earnings today.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Earnings Results

Avita share price dives 16% on net loss

The medical technology company's shares are falling following today's financial results

Read more »

Confused baby.
Earnings Results

‘Our future is looking bright’: Baby Bunting share price slips despite earnings milestone

The company's total sales surpassed $500 million last financial year.

Read more »

a man surrounded by huge piles of paper looks through a magnifying glass at his computer screen.
Earnings Results

IAG share price on watch as company reports $347 million in earnings

IAG has reported its FY22 results. Here are the details.

Read more »

A man waking up happy with a smile on his face and arms outstretched representing the hefty Adairs dividend yield
Earnings Results

ResMed share price on watch following solid FY22 growth

ResMed has released its full year results...

Read more »

Teenager holds model plane in the air against the background of a blue sky.
Earnings Results

Alliance Aviation share price lifts despite full-year loss

Qantas' takeover target posted lower earnings for financial year 2022 despite its revenue increasing 19%.

Read more »